MRI Contrast Agents and Iron Oxide Nanoparticles for Cancer and Neurological Disease
This community develops magnetic resonance imaging (MRI) contrast agents, specifically iron oxide nanoparticles and gadolinium-based compounds, to improve the diagnosis and treatment of cancers like hepatocellular carcinoma and breast cancer, as well as neurological conditions such as multiple sclerosis.
The research focuses heavily on the synthesis and application of superparamagnetic iron oxide nanoparticles (SPIONs) and gadolinium-based contrast agents. Key applications include dynamic contrast-enhanced MRI, diffusion-weighted imaging, and magnetic hyperthermia for cancer therapy. The work also integrates deep learning and machine learning algorithms to analyze imaging data for diagnosis. Specific clinical targets include hepatocellular carcinoma, breast cancer, prostate cancer, and multiple sclerosis, with a significant portion of the literature dedicated to evaluating these agents in clinical settings and developing new nanoplatforms for drug delivery and theranostics.
The largest share of the community's output is found in gadolinium research, accounting for 23.3% of all gadolinium research, and 8,932 papers here. Iron research contributes 5.0% of its total output, with 5,392 papers in this group.
The community comprises 52,555 papers, published primarily in the Journal of Magnetic Resonance Imaging, Magnetic Resonance Imaging, and Magnetic Resonance in Medicine.
Recent work continues to focus on the clinical translation of superparamagnetic iron oxide nanoparticles, including their use in magnetic hyperthermia and as theranostic platforms for cancer, alongside ongoing studies on multiple sclerosis pathogenesis and brain clearance mechanisms.